@inbook{3eb883573bb341fab570489fc0247d09,
title = "STAT3 Inhibitors in Cancer: A Comprehensive Update",
abstract = "STAT3 is an important signaling molecule that modulates a wide range of genes by relaying extracellular signals from the plasma membrane to the nucleus in response to peptide hormone binding. It is known to play a prominent role in the initiation and progression of cancer, as it is constitutively activated in 25–100 % of more than 25 different malignancies and has been implicated in nearly all the hallmarks of cancer. In addition, STAT3 contributes to development and maintenance of cancer stem cells, as well as to cancer immune evasion and resistance to chemotherapy and radiotherapy, making it an even more attractive target for cancer therapy. In this chapter, we give an overview of strategies involved in targeting STAT3 and discuss recent advances in the development of STAT3 modulating agents.",
keywords = "Allosteric, Aptamer, Cancer, Clinic, Clinical trial, Decoy, Drug design, Dysregulated, High throughput screen, Inhibitor, Interference, Kinase, Nuclear, Oncogene, Peptidomimetics, Phosphorylation, Rational, Resistance, SH2, Signaling, STAT3, Therapeutic, Transcriptional activation",
author = "Uddalak Bharadwaj and Kasembeli, {Moses M.} and Tweardy, {David J.}",
note = "Publisher Copyright: {\textcopyright} Springer International Publishing Switzerland 2016.",
year = "2016",
doi = "10.1007/978-3-319-42949-6_5",
language = "English (US)",
series = "Cancer Drug Discovery and Development",
publisher = "Humana Press Inc.",
pages = "95--161",
booktitle = "Cancer Drug Discovery and Development",
}